rabeprazole + domperidone

Rabeprazole plus domperidone is a fixed-dose combination therapy developed by Atlina Life Sciences, typically formulated as a capsule containing enteric-coated rabeprazole sodium (40 mg) and sustained-release domperidone (30 mg). Rabeprazole is a proton pump inhibitor (PPI) that covalently binds to and inhibits the gastric H+/K+ ATPase enzyme, thereby reducing gastric acid secretion. Domperidone is a peripheral dopamine D2 receptor antagonist that acts as a prokinetic agent, enhancing gastric motility and reducing nausea by facilitating gastric emptying. This combination is indicated for the treatment of gastroesophageal reflux disease (GERD), dyspepsia, and other acid-related disorders where impaired gastric motility is a contributing factor. By addressing both acid overproduction and delayed gastric emptying, the therapy provides comprehensive relief for patients who may not respond adequately to PPI monotherapy.

Brand names

Rabsig DSRRabsig DSR 40mg

Other names

rabeprazole + domperidoneRabeprazole/Domperidone